139 related articles for article (PubMed ID: 36524437)
1. Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis.
Krause KJ; Goldrich D; Gniady J
Laryngoscope; 2023 Apr; 133(4):863-865. PubMed ID: 36524437
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
4. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Matucci A; Maggi E; Vultaggio A
Respir Med; 2019; 160():105819. PubMed ID: 31734469
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
8. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
9. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
[TBL] [Abstract][Full Text] [Related]
10. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
11. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
12. Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Ghazi A; Trikha A; Calhoun WJ
Expert Opin Biol Ther; 2012 Jan; 12(1):113-8. PubMed ID: 22136436
[TBL] [Abstract][Full Text] [Related]
13. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
14. Reductions in eosinophil biomarkers by benralizumab in patients with asthma.
Pham TH; Damera G; Newbold P; Ranade K
Respir Med; 2016 Feb; 111():21-9. PubMed ID: 26775606
[TBL] [Abstract][Full Text] [Related]
15. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
16. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
17. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
DuBuske L; Newbold P; Wu Y; Trudo F
Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
[TBL] [Abstract][Full Text] [Related]
18. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
19. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
Liu T; Wang F; Wang G; Mao H
Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
